Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | FABP7 | O15540 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8299598 | 0.95 | TSHR (0.42) | TSHRCPB1FKBP1AGAAALDH1A1 | |
| SCHEMBL12406849 | 0.90 | TSHR (0.46) | TSHRCPB1FKBP1AALDH1A1MAPK1 | |
| SCHEMBL2171811 | 0.89 | CTSL (0.39) | TSHRCPB1FKBP1AALDH1A1MAPK1 | |
| SCHEMBL13015103 | 0.87 | TSHR (0.44) | TSHRCPB1FKBP1AALDH1A1MAPK1 | |
| SCHEMBL2172914 | 0.83 | ADAM10 (0.44) | TSHRFKBP1AALDH1A1POLBRAB9A | |
| SCHEMBL21361580 | 0.76 | ALDH1A1 (0.55) | TSHRCPB1GAAALDH1A1MAPK1 | |
| SCHEMBL21984268 | 0.76 | ALDH1A1 (0.55) | TSHRCPB1GAAALDH1A1MAPK1 | |
| SCHEMBL20581107 | 0.76 | ALDH1A1 (0.55) | TSHRCPB1GAAALDH1A1MAPK1 | |
| SCHEMBL27709631 | 0.75 | ALDH1A1 (0.60) | TSHRCPB1GAAALDH1A1CA1 | |
| SCHEMBL12282413 | 0.75 | TSHR (0.46) | TSHRCPB1FKBP1AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440958-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2015-01-22 | — | — | US | disclosed |
| US-8853243-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2014-10-07 | — | — | US | disclosed |
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-7973041-B2 | Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. | INCYTE CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1678167-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Incyte Corporation (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005037826-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP14, MMP9 | TSHR 3573/4885CPB1 158/4885FKBP1A 503/4885 |
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP2, MMP14 | TSHR 3634/4885CPB1 146/4885FKBP1A 442/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | TSHR 2962/4885CPB1 326/4885FKBP1A 389/4885 |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | TSHR 3634/4885CPB1 146/4885FKBP1A 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.